

1 **Heterogeneity of Inflammation-associated Synovial Fibroblasts in Rheumatoid Arthritis**  
2 **and Its Drivers.**

3  
4 Melanie H Smith<sup>1,2#</sup>, Vianne R Gao<sup>3#</sup>, Michail Schizas<sup>2</sup>, Alejandro Kochen<sup>4</sup>, Edward F DiCarlo<sup>5</sup>,  
5 Susan M Goodman<sup>1,6</sup>, Thomas M Norman<sup>3</sup>, Laura T Donlin<sup>4,6</sup>, Christina S Leslie<sup>3</sup>, and Alexander  
6 Y Rudensky<sup>2</sup>

7  
8 <sup>1</sup> Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY  
9 10021, USA.

10 <sup>2</sup> Howard Hughes Medical Institute and Immunology Program at Sloan Kettering Institute, Ludwig  
11 Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY  
12 10065, USA.

13 <sup>3</sup> Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New  
14 York, NY 10065, USA

15 <sup>4</sup> Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research  
16 Center, Hospital for Special Surgery, New York, NY 10021, USA.

17 <sup>5</sup> Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY  
18 10021, USA.

19 <sup>6</sup> Weill Cornell Medical College and Graduate School, New York, NY 10021, USA.

20 #These authors made equal contributions.

21

22 Address correspondence to: Melanie H Smith ([smithmel@hss.edu](mailto:smithmel@hss.edu)), Christina S Leslie  
23 ([cleslie@cbio.mskcc.org](mailto:cleslie@cbio.mskcc.org)), Alexander Y Rudensky ([rudenska@mskcc.org](mailto:rudenska@mskcc.org))

24 **Abstract**

25 Inflammation of non-barrier immunologically quiescent tissues is associated with a massive influx  
26 of blood-borne innate and adaptive immune cells. Cues from the latter are likely to alter and  
27 expand the spectrum of states observed in cells that are constitutively resident. However, local  
28 communications between immigrant and resident cell types in human inflammatory disease  
29 remain poorly understood. Here, we explored heterogeneity of synovial fibroblasts (FLS) in  
30 inflamed joints of rheumatoid arthritis (RA) patients using paired single cell RNA and ATAC  
31 sequencing (scRNA/ATAC-seq), multiplexed imaging, and spatial transcriptomics along with *in*  
32 *vitro* modeling of cell extrinsic factor signaling. These analyses suggest that local exposures to  
33 myeloid and T cell derived cytokines,  $TNF\alpha$ ,  $IFN\gamma$ ,  $IL-1\beta$ , or lack thereof, drive six distinct FLS  
34 states some of which closely resemble fibroblast states in other disease-affected tissues including  
35 skin and colon. Our results highlight a role for concurrent, spatially distributed cytokine signaling  
36 within the inflamed synovium.

37 Rheumatoid arthritis (RA), a systemic autoimmune disease with predominantly articular  
38 manifestations, is characterized by hyperplasia of both the synovial lining, which interfaces the  
39 synovial sublining and the synovial fluid-filled joint space, as well as the synovial sublining, which  
40 exhibits increased vascularization and an influx of leukocytes. Both the lining and sublining  
41 fibroblast-like synoviocytes (FLS) undergo proliferation and activation, assuming a state, in which  
42 they stimulate angiogenesis, produce pro-inflammatory cytokines and chemokines, and invade  
43 adjacent articular cartilage and bone<sup>1</sup>. Expression of MHC class II molecules by activated FLS is  
44 associated with synovial inflammation<sup>2,3</sup> and their expression by lining FLS correlates with active  
45 disease<sup>4</sup>. HLA-DR<sup>+</sup> FLS expression of soluble mediators, including the proinflammatory cytokines  
46 IL-6 and IL-15, and chemokines CCL2, CXCL9, and CXCL12 along with adhesion molecules such  
47 as ICAM1 and VCAM1 suggests that these features of FLS might be imparted by their interactions  
48 with leukocytes<sup>2</sup>. In support of this possibility, prior *in vitro* studies have shown that HLA-DR<sup>+</sup> FLS  
49 are capable of presenting antigens to CD4<sup>+</sup> T cells<sup>5-7</sup>. Furthermore, production of the  
50 aforementioned proinflammatory chemokines by FLS likely acts as a feedforward mechanism to  
51 further facilitate recruitment of diverse immune cell types expressing the corresponding receptors.  
52 Indeed, a recent study of the overall cellular makeup of synovial tissue from RA patients using  
53 single cell RNA sequencing (scRNA-seq) analysis identified a diverse mix of migratory and  
54 resident cell types of hematopoietic and non-hematopoietic origin including different CD4 and  
55 CD8 T cell subsets, myeloid cells, and FLS<sup>2</sup>. These observations suggest that states of FLS  
56 activation and differentiation are likely modulated by diverse innate and adaptive immune cell  
57 types found in inflamed joints of RA patients and that this modulation factors prominently in the  
58 disease pathogenesis.

59

60 Thus, we sought to undertake an in-depth investigation of the spectrum of FLS states induced in  
61 the inflamed RA synovium and potential drivers underlying the observed FLS heterogeneity  
62 through paired scRNA and assay for transposase-accessible chromatin with sequencing  
63 (scRNA/ATAC-seq) and *in vitro* modeling of FLS transcriptional responses to key immune cell-  
64 derived proinflammatory cytokines. We then mapped the spatial distribution of FLS heterogeneity  
65 and transcriptional responses by employing spatial transcriptomic (ST) analyses as well as  
66 multiplex imaging. Our studies suggest that spatially constrained FLS responses to three major  
67 leukocyte-derived cytokines, TNF $\alpha$ , IFN $\gamma$ , and IL-1 $\beta$ , or lack thereof, drive the formation of six  
68 distinct FLS states associated with synovial inflammation in RA.

69

70 **Results**

## 71 **Inflammation is associated with heightened FLS heterogeneity**

72 To test the possibility that severe joint inflammation in RA patients leads to a marked expansion  
73 of FLS heterogeneity, we sought to characterize their transcriptomes and chromatin accessibility  
74 at a single cell resolution. Fluorescence-activated cell sorting (FACS)-sorted FLS (CD45<sup>+</sup>CD31<sup>-</sup>  
75 PDPN<sup>+</sup>) were isolated from two RA patients with highly inflamed synovium, who had similar  
76 disease characteristics as well as histologic findings, and subjected to paired scRNA/ATAC-seq  
77 using the 10x Multiome platform (patients 1 and 2 in Table S1, Extended Data Fig. 1a). After  
78 extensive filtering, we obtained 15,736 FLS that clustered into 14 clusters based on the scRNA-  
79 seq datasets (Fig. 1a, Extended Data Fig. 1b-e, Table S2). Similar results were obtained with and  
80 without Mutual Nearest Neighbors (MNN) batch correction (Extended Data Fig. 1f,g). Using  
81 established characteristic markers<sup>2</sup>, some of which are shown in Fig. 1b, we identified lining,  
82 sublining and pan-synovial clusters. The latter clusters express genes characteristic of both  
83 sublining and lining FLS. Consistent with the high degree of synovial inflammation, MHC class II  
84 expression was widespread as HLA-DR expressing cells were found in all clusters except for  
85 cluster 13 (Fig. 1c). Our observation of a high fraction of lining FLS expressing HLA-DR was at  
86 odds with previous reports that HLA-DR<sup>+</sup> FLS represent a subset within the sublining FLS  
87 population<sup>2</sup>. Therefore, we independently assessed HLA-DR expression using multicolor  
88 immunofluorescence (IF) and confirmed the pan-synovial expression of HLA-DR on FLS (Fig. 1d).

89 In addition to capturing all FLS subsets previously identified in the RA synovium<sup>2,4</sup> (Fig. 1e),  
90 our focused analysis of FLS in highly inflamed tissue enabled identification of novel subsets of  
91 both sublining (clusters 0, 10, 11) as well as lining (clusters 4, 6, 9) FLS (Fig. 1e). The large  
92 number of lining FLS spanning multiple clusters included those sharing transcriptional signatures  
93 characteristic of FLS derived from patients with both active and remission RA<sup>4</sup>. These results  
94 suggest that a highly inflamed RA joint harbors a greatly expanded range of FLS states possibly  
95 representing a broad spectrum of the disease.

96 While each cluster had specific features, such as the expression of *NOTCH3* in cluster 8 that  
97 marks perivascular FLS<sup>8</sup>, gene set enrichment analysis (GSEA) of each cluster highlighted shared  
98 functionality between groups of clusters (Fig. 1f and Table S3). In fact, the assessment of cluster-  
99 by-cluster correlation, allowed us to define six FLS states each with distinct inferred functionality  
100 (Fig. 1g). The identified resting lining FLS state shared a transcriptional profile with lining FLS  
101 from RA patients in remission<sup>4</sup>. The cytokine-activated lining FLS state, which expressed elevated  
102 levels of HLA-DR, displayed an IFN $\gamma$  response gene signature and additional inflammatory  
103 response gene signatures. Pan-synovial HLA-DR<sup>high</sup> FLS were characterized by the highest  
104 expression of HLA-DR, and also displayed an IFN $\gamma$  response signature as well as



105 lysosome/endosome-related genes (*CD63*, *CTSD*, *NPC2*, *LAPTM4A*, *CTSK*, *CD68*, *CTSL*,  
106 *CTSA*, *HEXA*, *CTSF*, *GUSB*, *LAMP1*) suggesting their potential role as antigen-presenting cells  
107 in the inflamed synovium. A transcriptional profile of these pan-synovial HLA-DR<sup>high</sup> FLS closely  
108 resembled the one previously reported for lining FLS from patients with active RA<sup>4</sup>. The sublining  
109 FLS were enriched for cytokine signaling pathway genes, most notably TNF $\alpha$ , but also IFN $\gamma$  and  
110 IL-6. Of note, both the sublining and cytokine-activated sublining FLS states show evidence of  
111 STAT5 signaling possibly driven by IL-15. Finally, we observed that the transcriptomes of a subset  
112 of sublining FLS exhibited features expected for progenitor cells including the highest level of  
113 CD34 expression, and enrichment for expressed genes related to extracellular matrix (ECM)  
114 homeostasis and epithelial mesenchymal transition (EMT) (*MFAP5*, *FBN1*, *VCAN*, *TGFBR3*,  
115 *FBLN2*, *PRRX1*, *DCN*, *LAMA2*, *SFRP4*, *EDIL3*, *FBLN1*, *LGALS1*, *LOXL1*, *ADAM12*, *LOX*, *CD44*,  
116 *IGFBP4*, *LRP1*). Notably, the most differentially expressed gene for the progenitor state was PI16,  
117 which was recently described as a marker for one of two populations of universal mouse (“cross-  
118 tissue”) fibroblasts that can give rise to specialized fibroblast populations during development and  
119 upon perturbation<sup>9</sup>. Furthermore, the gene expression features of the progenitor FLS state we  
120 characterized showed extensive similarity to the PI16<sup>+</sup> cluster and enrichment for the “universal  
121 fibroblast gene signature” identified in a human perturbed-state fibroblast atlas (Extended Data  
122 Fig. 1h). Since tissue progenitor or “stem-like” cells can be frequently found as aggregates within  
123 distinct specialized anatomical niches commonly associated with vasculature, we explored spatial  
124 distribution of these CD34<sup>high</sup>THY1<sup>+</sup>PDPN<sup>+</sup> FLS using IF. However, we found them widely  
125 dispersed as solitary cells throughout the inflamed synovium without conspicuous association  
126 with the vascular endothelium (Extended Data Fig. 1i). This finding suggests a possibility that in  
127 highly inflamed RA synovium FLS regenerative capacity is preserved in a non-compartmentalized  
128 manner.

129

### 130 **Comparison with non-synovial fibroblasts shows shared functionality across tissues**

131 Previous cell population-based studies suggested distinct diversity of transcriptional features of  
132 human fibroblasts in different anatomical locations and heritable imprinting of their “topography”<sup>10</sup>.  
133 However, our observation of conserved “universal fibroblast” features of progenitor PI16<sup>+</sup> FLS  
134 suggested that there might be an overlap between disease-induced states of anatomically distinct  
135 tissue fibroblasts affected by different pathologies. Thus, we next sought to explore whether other  
136 FLS states we identified were tissue or disease-specific, namely, unique to the synovium or RA-  
137 associated inflammation, or alternatively, were shared with fibroblast populations observed in  
138 other diseases and tissues (Fig. 2, Extended Data Fig. 2). For this comparative analysis, we took

139 advantage of several recent scRNA-seq datasets of colonic<sup>11,12</sup> and dermal fibroblasts<sup>13,14</sup>, in  
140 which at least 5 fibroblast clusters can be delineated.

141 As expected from the aforementioned presence of the “universal fibroblast signature”, the  
142 progenitor FLS state shared transcriptional similarity with fibroblasts from both the colon and skin.  
143 In the colon, this transcriptional signature was observed in two fibroblast populations implicated  
144 in creating an intestinal stem cell niche: ECM producing fibroblasts and myofibroblasts. In the  
145 skin, this transcriptional signature was observed in fibroblasts from unwounded skin responsible  
146 for ECM homeostasis and in a fibroblast population that undergoes contraction in scleroderma as  
147 compared to healthy skin.

148 Unexpectedly, we observed a remarkable transcriptional similarity between inflammatory  
149 cancer associated fibroblasts in colorectal cancer and the HLA-DR<sup>+</sup> cytokine-activated lining FLS.  
150 The latter FLS state was also similar to transcriptional states of fibroblasts in diabetic foot ulcers  
151 that were able to successfully heal.

152 On the other hand, transcriptional features of fibroblasts in the diseased skin or colon bore  
153 only limited similarity to both the resting lining and cytokine-activated sublining FLS states we  
154 observed. The resting lining FLS were characterized by high expression of genes involved in the  
155 production of synovial fluid and ECM (*XYLT1*, *FN1*, *ITGB8*, *PRG4*) and axonal guidance  
156 (*SEMA5A*, *ANK3*, *NTN4*, *SLIT2*), features which likely reflect their specialized functions within the  
157 synovium. The cytokine-activated sublining FLS state also appeared distinct to the RA synovium,  
158 however, it likely emerged due to the high degree of inflammation in the RA synovial samples we  
159 analyzed. Accordingly, corresponding fibroblast states in other tissues are expected to be found  
160 only under similarly highly inflamed conditions and may not have been enriched in the scRNA-  
161 seq datasets used for the cross-comparison. Thus, inflammation-induced perturbations in the  
162 overall composition of the FLS population and spectrum of FLS states were shared with  
163 fibroblasts found in other tissues in a range of pathologies.

164

### 165 **FLS states exhibit distinct transcriptional regulation with evidence of differential cytokine** 166 **stimulation**

167 To gain insight into transcription factors and upstream signaling pathways which promoted FLS  
168 heterogeneity in RA, we analyzed paired scATAC-seq datasets. Unsupervised clustering resulted  
169 in seven clusters with lining and sublining FLS subtypes as well as an independent cluster of  
170 progenitor-like FLS (Fig. 3a,b, Extended Data Fig. 3a-c). Distinct FLS states identified by scRNA-  
171 seq analyses occupied divergent areas of the scATAC-seq UMAP (Fig. 3c) partially overlapping  
172 with the identified scATAC-seq clusters (Extended Data Fig. 3d). To infer differential transcription

173 factor activity in identified FLS states, we performed chromatin accessibility variation analysis  
174 using chromVAR. For this analysis, we used the paired scRNA-seq data as a filter to assess only  
175 motifs for the transcription factor families whose members were expressed by >20% of cells in  
176 the corresponding state. We observed marked differences in enrichment of distinct transcription  
177 factor binding motifs within open chromatin sites with differential motif accessibility between states  
178 (Fig. 3d,e). The cytokine-activated lining and HLA-DR<sup>high</sup> pan-synovial FLS states were enriched  
179 for activity of AP-1 transcription factor family members (JUN, JUNB, JUND, FOS, FOSL2), whose  
180 increased contribution to gene regulation downstream of fibroblast growth factor (FGF) and  
181 immune receptor signaling, such as IL-1, has been suggested to play a role in tissue-destructive  
182 properties of FLS in RA<sup>15,16</sup>. Interestingly, open chromatin sites characteristic of the cytokine-  
183 activated sublining FLS state were enriched for STAT and IRF family motifs implicating a distinct  
184 set of inflammatory pathways such as IFN signaling in establishing this state. Contrary to the two  
185 major flavors of activated, inflammation-associated FLS, the resting lining FLS state was  
186 distinguished by the accessibility of homeobox transcription factor family member motifs, which  
187 besides serving as major regulators of development and organization, control fibroblast  
188 quiescence (e.g., PRRX1)<sup>17,18</sup>. In support of a role for homeobox transcription factors in  
189 modulating FLS activation, the resting lining FLS state exhibited increased expression of  
190 homeobox family member *CUX1*, which has been shown to bind to NF-κB and alter its activity  
191 through either downregulation<sup>19</sup> or upregulation<sup>20</sup> of specific NF-κB-regulated cytokines and  
192 chemokines. Finally, the PI16<sup>+</sup> progenitor FLS were distinguished by accessible *cis*-regulatory  
193 elements enriched for KLF, SOX and TEAD family motifs, which play a role in maintaining  
194 quiescent undifferentiated states in stem cells and early progenitors. In this regard, KLF4 has  
195 been implicated in the induction of a pluripotent state in fibroblasts consistent with the likely role  
196 of this FLS subset as progenitors<sup>21</sup>. These results suggest that distinct states of FLS in the  
197 inflamed RA joint were dependent upon their local stimulation by immune cell derived factors,  
198 foremost proinflammatory cytokines, or avoidance of these inflammatory exposures.

199

### 200 **Cytokine signaling drives transcriptional heterogeneity**

201 To test the above possibility and to elucidate influences of inflammatory factors on transcriptomes  
202 of FLS states we sought to deconvolute their complex transcriptomes by establishing cell-type  
203 specific cytokine-induced programs. For identification of immune cell derived cytokine  
204 transcriptional responses and their contributions to distinct features of FLS state-specific  
205 transcriptomes, we employed *in vitro* stimulation of cultured FLS by candidate pro-inflammatory  
206 cytokines and other factors. For these experiments, FLS were isolated from four RA synovial

207 tissue samples and cultured for three passages prior to pooling FLS from all donors and  
208 performing the stimulations in triplicate. FLS were stimulated with three major cytokines implicated  
209 in RA –  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$  and  $\text{IL-1}\beta$ , either individually or in combination – and the resulting gene  
210 expression changes were assessed using RNA-seq (Fig. 4a, Table S4). Additionally, to directly  
211 compare cytokine stimulation effects on a per patient basis, we isolated FLS from the same RA  
212 synovial tissue samples subjected to scATAC/RNA-seq (Figs. 1 and 3) stimulated them with  
213  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$  and  $\text{IL-1}\beta$  or  $\text{TNF}\alpha$  and  $\text{IFN}\gamma$  and performed scATAC/RNA-seq. We found that *in vitro*  
214 stimulation of FLS with both  $\text{TNF}\alpha$  and  $\text{IFN}\gamma$  induced expression of genes including *CCL2* and  
215 *IL6*, which were highly expressed by *ex vivo* isolated cytokine-activated sublining FLS. On the  
216 other hand, genes whose expression was markedly suppressed in response to these cytokines  
217 (e.g., *VCAN*, *CCDC80*, *CD248* in Fig. 4a) were highly upregulated by the  $\text{CD34}^{\text{high}}\text{THY1}^+\text{PI16}^+$   
218 FLS suggesting that the progenitor FLS state is shielded from exposure to inflammatory mediators  
219 and that these cytokines may lead to the loss of this state. In the same vein, *ANK3*, which is  
220 upregulated in the resting lining FLS state, was also downregulated in response to *in vitro*  
221 stimulation by  $\text{TNF}\alpha$  and  $\text{IFN}\gamma$  suggesting that besides the progenitor FLS in the sublining, resting  
222 lining FLS also appear to be spared from the full effects of inflammatory cytokines. Finally, genes  
223 induced in FLS subjected to *in vitro* stimulation by the combination of  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$  and  $\text{IL-1}\beta$ , which  
224 included *MMP3* and *CXCL1*, were most differentially expressed in *ex vivo* isolated cytokine-  
225 activated lining FLS.

226 Notch signaling induced by ligands expressed by the vascular endothelium have been  
227 suggested to factor prominently in the differentiation of perivascular and sublining FLS in the RA  
228 synovium<sup>8</sup>. This raised the question as to whether Notch signaling can potentially modulate  
229 transcriptional responses of FLS to pro-inflammatory cytokines within the sublining. To explore  
230 this possibility, we investigated changes in gene expression induced in FLS upon stimulation with  
231  $\text{TNF}\alpha$ ,  $\text{IFN}\gamma$  and  $\text{IL-1}\beta$  in the presence or absence of plate-bound Notch ligand Delta like-4 (DLL4).  
232 This analysis revealed a global dampening of transcriptional responses to all three cytokines (Fig.  
233 4b, Table S5): for both up- and down-regulated genes, the observed changes were blunted across  
234 the board. DLL4 similarly attenuated transcriptional responses to dual and triple combinations of  
235 cytokines ( $\text{TNF}\alpha + \text{IFN}\gamma$  and  $\text{TNF}\alpha + \text{IFN}\gamma + \text{IL-1}\beta$ , respectively) (data not shown). This finding  
236 was unexpected considering that previous studies suggested that Notch signaling augments  
237 macrophage responses to TLR ligands and increases production of pro-inflammatory cytokines<sup>22</sup>.  
238 However, there may be multiple specific regulatory mechanisms in play as previous reports also  
239 show that  $\text{IFN}\gamma$  can inhibit Notch signaling in macrophages<sup>23</sup>. These results raise an intriguing

240 question as to whether coincident engagement of inflammatory and developmental signaling  
241 pathways may result in different functional outcomes depending on a given cell type.

242 Mapping of cytokine response gene signatures established by the above *in vitro* analyses  
243 onto our scRNA-seq datasets revealed the most pronounced expression of these gene signatures  
244 in the cytokine activated lining FLS state (Fig. 4c). In contrast, the dominant cytokine response  
245 signatures in the cytokine-activated sublining FLS state included either genes modulated by a  
246 dual combination of TNF $\alpha$  and IFN $\gamma$  or by IFN $\gamma$  alone. Notably, the progenitor state was devoid of  
247 cytokine response gene signatures.

248 Previous scRNA-seq analysis suggests that CD8<sup>+</sup> T cells represent the major source of IFN $\gamma$   
249 in the RA synovium<sup>2</sup>. In agreement with previous reports, our imaging showed predominant  
250 localization of CD8<sup>+</sup> T cells within lymphoid aggregates in the sublining region. Therefore, we  
251 sought to investigate whether local FLS interferon responses correlated with CD8<sup>+</sup> T cell  
252 localization *in situ* by analyzing phosphorylated STAT1 (pSTAT1), the key downstream target of  
253 interferon signaling, using IF (Fig. 4d). Interestingly, we observed nuclear pSTAT1 in PDPN<sup>+</sup> FLS  
254 within both lymphocyte aggregates in the sublining region as well as the T cell poor lining region.  
255 Of note, some of the PDPN<sup>+</sup>pSTAT1<sup>+</sup> FLS also express HLA-DR consistent with a well-recognized  
256 role of IFN $\gamma$  in driving MHC class II expression, while pSTAT1 observed in T cell poor regions  
257 may reflect local type I IFN signaling.

258 To further validate the effect of cytokine stimulation on regulation of gene expression, we  
259 performed scATAC-seq of cultured FLS stimulated with combinations of cytokines to cross-  
260 reference the observed transcription factor motif activity at modulated chromatin accessibility sites  
261 to that of distinct FLS states revealed by scATAC-seq analyses of *ex vivo* isolated cells (Fig. 4e).  
262 We found that stimulation of FLS with a combination of TNF $\alpha$  and IFN $\gamma$  resulted in enrichment of  
263 IRF and STAT family transcription factor motifs at differentially accessible chromatin sites in  
264 comparison to unstimulated FLS, closely matching those in the cytokine-activated sublining state  
265 of FLS *ex vivo*. In contrast, triple combination of TNF $\alpha$ , IFN $\gamma$  and IL-1 $\beta$  resulted in differential  
266 chromatin remodeling at sites enriched for AP-1 transcription factor family motifs. The latter  
267 observation was consistent with a previous report of remodeling of chromatin regions containing  
268 NF-kB and AP-1 binding motifs in response to IL-1 $\beta$ <sup>24</sup>. Impressively, the differentially accessible  
269 sites enriched for AP-1 family motifs were nearly identical to those observed in the *ex vivo* isolated  
270 cytokine-activated lining FLS state. The comparison of cytokine-stimulated samples to the  
271 unstimulated control explains the seemingly unexpected decrease in accessibility of *cis*-  
272 regulatory elements containing STAT motifs in the cytokine-activated lining FLS (Fig. 3d) despite  
273 the presence of a robust IFN $\gamma$  response gene expression signature (Fig. 4c) and STAT1

274 phosphorylation (Fig. 3d) (Extended Data Fig. 4). Thus, this was most likely due to a relative  
275 decrease in STAT accessibility of a subset of these elements caused by combined IL-1 $\beta$ , IFN $\gamma$   
276 and TNF $\alpha$  exposure while the corresponding transcript levels were not markedly impacted.  
277 Together, these analyses of transcriptomes and epigenomes strongly support a role of  
278 combinatorial stimulation by TNF $\alpha$  and IFN $\gamma$  in facilitating the establishment of the cytokine-  
279 activated sublining FLS state whereas the cytokine-activated lining FLS state was likely driven by  
280 a triple combination of TNF $\alpha$ , IFN $\gamma$  and IL-1 $\beta$ .

281

### 282 **Cytokine signaling is spatially constrained and correlated with cellular localization**

283 The observations above suggest that distinct states of FLS in the inflamed synovium are  
284 established in a spatial manner as the result of locally produced inflammatory cytokines and other  
285 mediators by distinct types of immune cells invading the RA synovium. To define the spatial  
286 distribution of identified FLS states within the RA synovium, we performed spatial transcriptomic  
287 (ST) analyses using the 10x Visium platform combined with multiplex IF imaging of adjacent tissue  
288 sections for two additional inflamed synovial tissue samples isolated from RA patients (patients 3  
289 and 4 in Table S1). The hematoxylin and eosin (H&E) staining of the sections subjected to ST  
290 analysis showed prominent lymphocyte aggregates as well as copious synovial lining (Fig. 5a).  
291 IF imaging of the sections adjacent to those used for ST showed scattered PDPN<sup>+</sup> FLS and CD68<sup>+</sup>  
292 macrophages as well as lymphocyte aggregates in the sublining region, and multiple regions of  
293 lining populated by FLS and macrophages (Fig. 5b). The ST datasets were integrated with our  
294 scRNA-seq analyses to map the transcriptional signatures from the six FLS states on the ST  
295 datasets. This showed that the resting and cytokine-activated lining FLS appeared to intermix  
296 without forming well-defined regions. In contrast, the three identified sublining FLS subsets were  
297 differentially localized (Fig. 5c). We next applied the *in vitro* FLS cytokine response gene  
298 signatures to spatial gene expression maps derived from ST analysis. We found that the IL-1 $\beta$   
299 response signature mapped predominantly to the synovial lining, while the other cytokine  
300 response signatures were more scattered (Fig. 5d). Since multiple cells contribute to each RNA  
301 capture spot on a Visium slide, we confirmed that the IL-1 $\beta$  response gene signature observed in  
302 ST analysis was contributed by FLS rather than other cell types by creating a modified IL-1 $\beta$   
303 response gene signature that only contained genes uniquely expressed by FLS based on recent  
304 scRNA-seq analysis of RA synovium<sup>2</sup>. Integrated ST and IF imaging analysis of adjacent sections  
305 showed that the cytokine-activated lining FLS state featuring the IL-1 $\beta$  response gene signature  
306 was near areas densely populated by CD68<sup>+</sup> macrophages. Mapping cell type specific



307 transcriptional signatures from a recent scRNA-seq analysis of the RA synovium<sup>2</sup> onto the spatial  
308 gene expression datasets confirmed the colocalization of monocyte/macrophages with the IL-1 $\beta$   
309 response gene signature (Fig. 5e). Similar analyses of an independent RA sample confirmed  
310 these results (Extended Data Fig. 5a-e). This association was further validated by an unbiased  
311 correlation of the FLS states, cytokine response gene signatures, and cell type specific gene  
312 signatures within individual spots that showed a correlation between monocytes/macrophages,  
313 lining FLS and the IL-1 $\beta$  response gene signature (Extended Data Fig. 5f). These results suggest  
314 that cytokine signaling shapes multiple spatially distinct microenvironments within the inflamed  
315 RA synovium with IL-1 $\beta$  from either resident macrophages or infiltrating monocytes defining the  
316 synovial lining FLS.

317

### 318 **Discussion**

319 Phenotypic and functional heterogeneity of parenchymal cells within a given tissue depends on  
320 both constant cell-intrinsic differentiation programs and cell extrinsic cues afforded by stable and  
321 transient interactions with tissue resident and infiltrating cells. The latter are represented for the  
322 most part by diverse types of immune cells, which, when activated, produce cytokines and other  
323 mediators that can act on the parenchymal cells changing the range of their physiological or  
324 homeostatic states. In RA, the synovium, which is in health a non-barrier immunologically  
325 quiescent tissue, experiences a massive influx of both innate and adaptive immune cells. In this  
326 setting, FLS experience differentiation signals, such as the endothelium-derived Notch signaling  
327 gradient that shapes FLS in the synovial sublining region<sup>8</sup>, and coincident exposures to multiple  
328 cytokine and other inflammatory mediators. Using paired scRNA/ATAC-seq and ST analyses  
329 assisted by *in vitro* generated cytokine response signatures, we demonstrated that leukocyte-  
330 derived cytokines play a key role in the formation of discrete, spatially defined, but likely dynamic  
331 FLS states with distinct inferred functionality. We also observed, contrary to a reported  
332 potentiation of inflammatory cytokine responses in macrophages<sup>22</sup>, Notch activation in FLS  
333 attenuated cytokine responses. This finding may explain the relatively dampened cytokine  
334 response gene signatures observed in the sublining FLS state, which was distinguished by the  
335 highest *NOTCH3* expression, as compared to the cytokine-activated sublining FLS state.

336 Our analysis of rich paired datasets of single cell transcriptomes and epigenomes allowed us  
337 to detect previously unappreciated heterogeneity of FLS in highly inflamed RA synovium,  
338 including an inflamed sublining state driven by IFN $\gamma$  and TNF $\alpha$  and two lining states defined by  
339 differential cytokine responses. The observation that the cytokine-activated lining FLS  
340 transcriptome was enriched for genes downstream of IFN $\gamma$ , TNF $\alpha$  and IL-1 $\beta$  was consistent with

341 the expression of the latter two cytokines by synovial macrophages<sup>2</sup>, and the coincident  
342 positioning of macrophages with the local IL-1 $\beta$  signature in the synovial lining in our ST analysis.  
343 Potential sources of IFN $\gamma$  and STAT1 activation within the synovial lining remained less clear.  
344 While CD8<sup>+</sup> T cells have been described as the dominant producers of IFN $\gamma$  within the synovium,  
345 it is possible that other cells such as NK cells<sup>3</sup> or myeloid cells<sup>25</sup> may contribute. Finally, it is  
346 probable that the prominent pSTAT1 signal observed in the synovial lining FLS (Fig. 4c), which  
347 has also been reported previously<sup>26</sup>, is the result of the action of alternative drivers of STAT1  
348 activation including type I IFN<sup>26</sup>, whose expression can be driven by IL-1 $\beta$ <sup>27</sup>.

349 The prominent IL-1 $\beta$  response signature in the cytokine-activated lining FLS state is notable  
350 given its possible functional and therapeutic implications. First, IL-1 $\beta$  is the primary inducer of  
351 MMPs, which have been implicated in FLS invasiveness<sup>28</sup>. This invites the possibility of a  
352 functional dichotomy between sublining and lining FLS in RA parallel to that observed in an  
353 experimental arthritis model in mice, where the lining FLS are uniquely responsible for destruction  
354 of cartilage and bone<sup>29</sup>. Blocking IL-1 may antagonize the capacity of FLS to assume this MMP  
355 expressing lining state and, thus it is possible that for a subset of patients the addition of IL-1  
356 inhibition during flares could prove effective for preventing joint destruction. Second, the cytokine-  
357 activated lining FLS state may drive migration of neutrophils into the synovial fluid, where there is  
358 a surfeit of neutrophils during RA flares. In this regard, the inflammatory cancer-associated  
359 fibroblasts in colorectal adenocarcinomas, which we found to share extensive transcriptional  
360 similarity with the cytokine-activated lining FLS state, express neutrophil chemoattractants  
361 including *CXCL1* and *CXCL8* and their location was spatially correlated with the accumulation of  
362 neutrophils<sup>11</sup>. In RA, IL-1 $\beta$  produced by macrophages in the lining region likely drives the high  
363 expression of *CXCL1* observed in the cytokine-activated lining FLS. Finally, the prominence of  
364 the cytokine-activated lining FLS state observed in highly inflamed RA synovium may have  
365 prognostic implications. A recent study of pathotypes in inflammatory bowel disease showed an  
366 association of an IL-1 $\beta$ -activated fibroblast signature with a lack of response to multiple  
367 therapies<sup>30</sup>.

368 Besides the cytokine-driven FLS states, we defined a CD34<sup>high</sup>THY1<sup>+</sup>PDPN<sup>+</sup> progenitor-like  
369 FLS population that was devoid of cytokine response signatures and shared extensive  
370 transcriptional similarity with fibroblast populations found in both the colon and skin. The  
371 abundance of this progenitor-like population appears to vary between synovial tissues of  
372 individual patients and may depend on disease activity or treatment. Future studies will help  
373 determine if the paucity of cytokine response gene signatures in these FLS owes to their



374 sequestration from cytokine-producing immune cells, or cell-intrinsic attenuation of cytokine  
375 signaling.

376 In conclusion, we established a spatial atlas of heterogeneity of synovial fibroblast states in  
377 RA defined by their distinct transcriptional signatures and patterns of chromatin accessibility  
378 driven by differential local exposure to immune cell-derived pro-inflammatory cytokines. The  
379 resulting datasets will serve as a rich resource for future investigation of RA pathogenesis through  
380 integration of unique and shared characteristics of inflamed synovial fibroblasts described herein  
381 with other disease-associated signals, such as complement activation<sup>31</sup>, and potential antigen  
382 presentation via HLA-DR.

383

#### 384 **Acknowledgments:**

385 We thank HSS orthopedic surgeons, clinical research coordinators (particularly Diyu Fisher and  
386 Edoardo Spolaore) and the HSS patients who contributed to this study. We acknowledge the  
387 Accelerating Medicines Partnership® (AMP®) in Rheumatoid Arthritis and Lupus Network for the  
388 stimulating discussions and the large-scale sequencing of arthritis patient synovial tissues that  
389 formed the basis for this study. AMP is a public-private partnership (AbbVie Inc., Arthritis  
390 Foundation, Bristol-Myers Squibb Company, Foundation for the National Institutes of Health,  
391 GlaxoSmithKline, Janssen Research and Development, LLC, Lupus Foundation of America,  
392 Lupus Research Alliance, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious  
393 Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc.,  
394 Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.)  
395 created to develop new ways of identifying and validating promising biological targets for  
396 diagnostics and drug development.

397

398 **Funding:** This work was supported by HSS T32 5T32AR071302-04 (M.H.S.). NIAID R01  
399 AI034206-28 (A.Y.R.). NCI CA008748-55 (A.Y.R.). NHGRI U01 HG012103 (C.S.L., A.Y.R.,  
400 L.T.D., T.M.N.). R01 AI148435 (L.T.D.). UH2 AR067691 (L.T.D.). AYR is an investigator with  
401 Howard Hughes Medical Institute (HHMI) and is supported by the Ludwig Center for Cancer  
402 Immunotherapy at Memorial Sloan Kettering.

403

#### 404 **Author contributions:**

405 MHS conceived the project, collected clinical data, designed experiments, performed  
406 experiments, prepared figures, wrote the manuscript.

407 VRG analyzed sequencing data, prepared figures and edited the manuscript.

408 MS analyzed sequencing data.

409 AK performed experiments.

410 EFD scored histology slides.

411 SMG collected clinical data.

412 TMN designed experiments, supervised research experiments, analyzed sequencing data and  
413 prepared figures.

414 CSL oversaw the computational analysis and edited the manuscript.

415 LTD conceived the project, acquired funding, designed experiments, supervised research  
416 experiments, oversaw data analysis and edited the manuscript.

417 AYR conceived the project, acquired funding, designed experiments, supervised research  
418 experiments, oversaw data analysis and wrote the manuscript.

419

420 **Competing interests:** AYR is an SAB member, has equity in Sonoma Biotherapeutics and  
421 Vedanta Biosciences, and is a co-inventor or has IP licensed to Takeda that is unrelated to the  
422 content of the present study. The remaining authors declare no competing interests.

423

424 **Code availability:** The customized code used in the present study is publicly available at:  
425 [https://github.com/viannegao/RA\\_Fibroblast\\_Analysis](https://github.com/viannegao/RA_Fibroblast_Analysis)

426

427 **Data availability:** All sequencing data generated in this paper were deposited in the Gene  
428 Expression Omnibus (GEO) under accession numbers: (accession number to be generated)

429

430 All materials and data transferred between HSS and MSKCC were covered under material  
431 transfer agreements.

432

### 433 **References:**

434 1. Nygaard, G. & Firestein, G. S. Restoring synovial homeostasis in rheumatoid arthritis by  
435 targeting fibroblast-like synoviocytes. *Nat. Rev. Rheumatol.* **16**, 316–333 (2020).

436 2. Zhang, F. *et al.* Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues  
437 by integrating single-cell transcriptomics and mass cytometry. *Nat. Immunol.* **20**, 928–942  
438 (2019).

- 439 3. Zhao, S. *et al.* JAK inhibition prevents the induction of pro-inflammatory HLA-DR+ CD90+  
440 RA synovial fibroblasts by IFN $\gamma$ . *Arthritis Rheumatol. Hoboken NJ* (2021)  
441 doi:10.1002/art.41958.
- 442 4. Alivernini, S. *et al.* Distinct synovial tissue macrophage subsets regulate inflammation and  
443 remission in rheumatoid arthritis. *Nat. Med.* **26**, 1295–1306 (2020).
- 444 5. Boots, A. M., Wimmers-Bertens, A. J. & Rijnders, A. W. Antigen-presenting capacity of  
445 rheumatoid synovial fibroblasts. *Immunology* **82**, 268–274 (1994).
- 446 6. Tran, C. N. *et al.* Presentation of arthritogenic peptide to antigen-specific T cells by  
447 fibroblast-like synoviocytes. *Arthritis Rheum.* **56**, 1497–1506 (2007).
- 448 7. Carmona-Rivera, C. *et al.* Synovial fibroblast-neutrophil interactions promote pathogenic  
449 adaptive immunity in rheumatoid arthritis. *Sci. Immunol.* **2**, (2017).
- 450 8. Wei, K. *et al.* Notch signalling drives synovial fibroblast identity and arthritis pathology.  
451 *Nature* **582**, 259–264 (2020).
- 452 9. Buechler, M. B. *et al.* Cross-tissue organization of the fibroblast lineage. *Nature* **593**, 575–  
453 579 (2021).
- 454 10. Chang, H. Y. *et al.* Diversity, topographic differentiation, and positional memory in human  
455 fibroblasts. *Proc. Natl. Acad. Sci.* **99**, 12877–12882 (2002).
- 456 11. Pelka, K. *et al.* Spatially organized multicellular immune hubs in human colorectal cancer.  
457 *Cell* **184**, 4734-4752.e20 (2021).
- 458 12. Smillie, C. S. *et al.* Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative  
459 Colitis. *Cell* **178**, 714-730.e22 (2019).
- 460 13. Tabib, T. *et al.* Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in  
461 systemic sclerosis skin. *Nat. Commun.* **12**, 4384 (2021).
- 462 14. Theocharidis, G. *et al.* Single cell transcriptomic landscape of diabetic foot ulcers. *Nat.*  
463 *Commun.* **13**, 181 (2022).


- 464 15. Asahara, H. *et al.* Direct evidence of high DNA binding activity of transcription factor AP-1 in  
465 rheumatoid arthritis synovium. *Arthritis Rheum.* **40**, 912–918 (1997).
- 466 16. Shiozawa, S., Shimizu, K., Tanaka, K. & Hino, K. Studies on the contribution of c-fos/AP-1  
467 to arthritic joint destruction. *J. Clin. Invest.* **99**, 1210–1216 (1997).
- 468 17. Yeo, S.-Y. *et al.* A positive feedback loop bi-stably activates fibroblasts. *Nat. Commun.* **9**,  
469 3016 (2018).
- 470 18. Feldmann, K. *et al.* Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive  
471 Pancreatic Cancer Biology. *Gastroenterology* **160**, 346–361.e24 (2021).
- 472 19. Kühnemuth, B. *et al.* CUX1 modulates polarization of tumor-associated macrophages by  
473 antagonizing NF- $\kappa$ B signaling. *Oncogene* **34**, 177–187 (2015).
- 474 20. Slowikowski, K. *et al.* CUX1 and I $\kappa$ B $\zeta$  (NFKBIZ) mediate the synergistic inflammatory  
475 response to TNF and IL-17A in stromal fibroblasts. *Proc. Natl. Acad. Sci.* **117**, 5532–5541  
476 (2020).
- 477 21. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic  
478 and adult fibroblast cultures by defined factors. *Cell* **126**, 663–676 (2006).
- 479 22. Keewan, E. & Naser, S. A. The Role of Notch Signaling in Macrophages during  
480 Inflammation and Infection: Implication in Rheumatoid Arthritis? *Cells* **9**, 111 (2020).
- 481 23. Hu, X. *et al.* Integrated Regulation of Toll-like Receptor Responses by Notch and Interferon-  
482  $\gamma$  Pathways. *Immunity* **29**, 691–703 (2008).
- 483 24. Weiterer, S.-S. *et al.* Distinct IL-1 $\alpha$ -responsive enhancers promote acute and coordinated  
484 changes in chromatin topology in a hierarchical manner. *EMBO J.* **39**, e101533 (2020).
- 485 25. Bogdan, C. & Schleicher, U. Production of interferon- $\gamma$  by myeloid cells – fact or fancy?  
486 *Trends Immunol.* **27**, 282–290 (2006).
- 487 26. Kasperkovitz, P. V. *et al.* Activation of the STAT1 pathway in rheumatoid arthritis. *Ann.*  
488 *Rheum. Dis.* **63**, 233–239 (2004).

- 489 27. Aarreberg, L. D. *et al.* Interleukin-1 $\beta$  Induces mtDNA Release to Activate Innate Immune  
490 Signaling via cGAS-STING. *Mol. Cell* **74**, 801-815.e6 (2019).
- 491 28. Tolboom, T. C. A. *et al.* Invasive properties of fibroblast-like synoviocytes: correlation with  
492 growth characteristics and expression of MMP-1, MMP-3, and MMP-10. *Ann. Rheum. Dis.*  
493 **61**, 975–980 (2002).
- 494 29. Croft, A. P. *et al.* Distinct fibroblast subsets drive inflammation and damage in arthritis.  
495 *Nature* **570**, 246–251 (2019).
- 496 30. Friedrich, M. *et al.* IL-1-driven stromal-neutrophil interactions define a subset of patients with  
497 inflammatory bowel disease that does not respond to therapies. *Nat. Med.* (2021)  
498 doi:10.1038/s41591-021-01520-5.
- 499 31. Friščić, J. *et al.* The complement system drives local inflammatory tissue priming by  
500 metabolic reprogramming of synovial fibroblasts. *Immunity* **54**, 1002-1021.e10 (2021).
- 501 32. Krenn, V. *et al.* Grading of chronic synovitis—a histopathological grading system for  
502 molecular and diagnostic pathology. *Pathol. Res. Pract.* **198**, 317–325 (2002).
- 503 33. Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes  
504 and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol.* **16**, 278  
505 (2015).
- 506 34. Korotkevich, G. *et al.* Fast gene set enrichment analysis. 060012 (2021)  
507 doi:10.1101/060012.
- 508 35. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for  
509 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550  
510 (2005).
- 511 36. Granja, J. M. *et al.* ArchR is a scalable software package for integrative single-cell  
512 chromatin accessibility analysis. *Nat. Genet.* **53**, 403–411 (2021).
- 513 37. Zhang, Y. *et al.* Model-based Analysis of CHIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).

514 38. Bhardwaj, V. *et al.* snakePipes: facilitating flexible, scalable and integrative epigenomic  
515 analysis. *Bioinforma. Oxf. Engl.* **35**, 4757–4759 (2019).

516

517 **Figures:**




518



519 **Figure 1. Heterogeneity of HLA-DR<sup>+</sup> FLS in the inflamed RA synovium.** **a**, UMAP of 14 FLS  
520 clusters identified by scRNA-seq analysis with annotations of synovial localization. **b**, Heatmap of  
521 selected DEGs for each cluster colored by synovial localization. **c**, UMAP colored by logged,  
522 library size-normalized expression of HLA-DRA and dot plot showing relative expression of HLA-  
523 DRA, HLA-DRB1 and CD74. **d**, Representative confocal microscopy of PDPN (red), HLA-DR  
524 (green), CD3 (magenta) and nuclear marker (blue) from RA synovial tissue (N = 5 tissues). Pixels  
525 with the highest intensity (top 3%) for both PDPN and HLA-DR are colored in yellow. **e**, Dotplot  
526 showing the relative per cluster expression of previously published cluster-derived gene  
527 signatures: Zhang et al<sup>2</sup> above and Alivernini et al<sup>4</sup> below horizontal line. Box (bottom left) shows  
528 lining FLS signatures from patients in remission or with active disease from Alivernini et al. **f**,  
529 GSEA showing top 5 pathways from KEGG with FDR <0.1 for each of the states defined in G.  
530 The resting lining state did not have any statistically enriched pathways. **g**, Cluster by cluster  
531 correlation of the mean expression of highly variable genes in clusters from Fig. 1a with defined  
532 FLS states colored on UMAP.

533






534

535 **Figure 2. Shared functional gene expression programs in FLS and non-synovial fibroblasts**

536 **across tissues and diseases.** Dot plot showing relative expression of selected gene signatures

537 from published tissue fibroblast populations<sup>11-14</sup> in FLS clusters shown in Fig. 1a colored

538 according to FLS states defined in Fig. 1g.



539

540 **Figure 3. Chromatin accessibility analysis of FLS states reveals their distinct**

541 **transcriptional regulation.** **a**, UMAP of 7 FLS clusters identified by tile-based scATAC-seq

542 analysis. **b**, Annotations of synovial localization as well as the progenitor state on the scATAC-

543 seq UMAP. **c**, Projection of six FLS states onto scATAC-seq UMAP. **d**, Heat map with top 10


544 differentially accessible transcription factor motifs identified by ChromVAR for each FLS state

545 defined in Fig. 1g. Motifs filtered to include only those for which the corresponding transcription

546 factor was expressed by >20% of cells in the corresponding state. **e**, ChromVAR z-score projected

547 onto scRNA-seq UMAP for a selection of top differentially accessible transcription factor motifs

548 derived from each FLS state.



549


550 **Figure 4. Cytokine signaling drives transcriptional FLS heterogeneity.** **a**, Changes in gene

551 expression (log fold change) after combinatorial stimulation of cultured FLS by cytokines


552 indicated. **b**, Cultured FLS were treated with the individual cytokines indicated *in vitro* and

553 subjected to 3' RNA sequencing to identify genes that were up- (left) or down- (right) regulated.  
554 Box plots compare the distribution of log<sub>2</sub> fold changes in the expression of these genes (in  
555 stimulated versus control) in FLS treated with each cytokine alone or in combination with DLL4.  
556 Gray lines connect individual genes across conditions. **c**, Dot plot showing relative expression of  
557 the identified cytokine response signatures in each of the FLS states defined in Fig. 1g. **d**,  
558 Representative confocal images of phosphorylated STAT1 staining (cyan), PDPN (red), CD3  
559 (magenta), CD8 (white) and nuclear marker (blue) (N = 4 tissues). Pixels with the highest intensity  
560 (top 3%) for both PDPN and HLA-DR are colored in yellow. White arrows indicate FLS with  
561 nuclear pSTAT1 staining in the sublining and white arrowheads indicate FLS with nuclear pSTAT1  
562 staining in the lining. **e**, ChromVAR z-score of motifs from Fig. 3d in cultured FLS that were  
563 unstimulated, simulated with TNF $\alpha$  + IFN $\gamma$ , or stimulated with TNF $\alpha$ , IFN $\gamma$  and IL-1 $\beta$ .  
564





565  
566 **Figure 5. Cytokine signaling is spatially constrained and correlated with cellular**  
567 **localization.** **a**, H&E staining of a representative tissue section used for ST (patient 4 in Table  
568 S1). **b**, IF image from a serial tissue section directly adjacent to that used for ST analysis. The  
569 down staining is for the following markers: PDPN (red), CD68 (green), CD19 (cyan), and CD3  
570 (magenta). (N = 2 tissues for ST with 2 adjacent sections each) **c**, Relative expression of FLS  
571 states defined in Fig. 1g in each RNA capture area on the ST slide. **d**, Relative expression of FLS  
572 cytokine response signatures in each RNA capture area on the ST slide. **e**, Relative expression  
573 of synovial macrophage specific gene signature from Zhang et al<sup>2</sup> in each RNA capture area on  
574 the ST slide.



575

576 **Extended Data Figure 1: scRNA-seq analysis of FLS isolated from inflamed RA synovium.**

577 **a**, Gating strategy for FACS sorting of FLS. **b**, Individual FLS clusters shown on UMAP. **c**,


578 Numbers of UMI counts and unique genes expressed in each cell shown on UMAP. **d**, Cell cycle

579 G2M score per cell shown on UMAP. **e**, Cluster composition by patient. **f**, Distribution of cells from

580 each patient without batch correction. **g**, Distribution of cells from each patient with MNN batch

581 correction. **h**, Dot plot with relative expression of fibroblast signatures from all clusters defined by  
582 the human perturbed fibroblast atlas from Buechler et al<sup>9</sup>. **i**, Representative confocal image of  
583 PDPN (red), THY1 (orange), CD34 (white), CD31 (green), CD3 (magenta) and nuclear marker  
584 (blue) from RA synovial tissue (N = 4 tissues). White arrow indicates individual CD34<sup>+</sup>, THY1<sup>+</sup>,  
585 PDPN<sup>+</sup> cell not within the vasculature.  
586






587

588 **Extended Data Figure 2: Expression of non-synovial fibroblast gene signatures in FLS.** Dot  
 589 plot showing relative expression of all gene signatures from published tissue fibroblast  
 590 populations<sup>11-14</sup> in FLS clusters shown in Fig. 1a colored according to FLS states defined in Fig.  
 591 1g.





592

593 **Extended Data Figure 3: Paired scATAC-seq analysis of isolated FLS. a,** Logged number of


594 fragments detected in each cell shown on UMAP. **b,** Distribution of cells from each patient. **c,**

595 scATAC-seq cluster composition by patient. **d,** scATAC-seq cluster composition by FLS states.

596


597

598



599

600 **Extended Data Figure 4: Dynamics of chromatin accessibility of STAT motif containing cis-**  
601 **regulatory elements across *in vivo* FLS states and *in vitro* cytokine stimulated or**  
602 **unstimulated FLS.** Empirical cumulative distribution function (ECDF) 600 plots of ChromVAR z-  
603 scores for STAT motifs from scATAC-seq analysis of the indicated FLS samples or states are  
604 shown.



605

606

607

608

**Extended Data Figure 5: Spatial transcriptomic analysis of inflamed RA synovial tissue. a,**  
**H&E staining of a tissue section used for ST (patient 3 in Table S1). b,**  
**IF image from a serial**  
**tissue section directly adjacent to that used for ST stained for: PDPN (red), CD68 (green), CD19**

609 (cyan), and CD3 (magenta). **c**, Relative expression of gene signatures of FLS states defined in  
610 Fig. 1g in each RNA capture area on the ST slide. **d**, Relative expression of FLS cytokine  
611 response gene signatures in each RNA capture area on the ST slide. **e**, Relative expression of  
612 synovial cell type specific gene signatures from Zhang et al<sup>2</sup> in each RNA capture area on the ST  
613 slide. **f**, Correlation between FLS state gene signatures derived from scRNA-seq data (from c), *in*  
614 *vitro* cytokine response gene signatures (from d), and cell type specific gene signatures (from e)  
615 within individual RNA capture spots.

616

617

618 **Supplementary Information**

619

620 **Table S1:** Patient characteristics for synovial tissue samples used in this study. Samples from  
621 patients 1 and 2 were used for the paired scRNA and scATAC sequencing. Samples from patients  
622 3 and 4 were used for spatial transcriptomics.

623 **Table S2:** Differentially expressed genes for clusters defined in Fig. 1a and states defined in Fig.  
624 1g.

625 **Table S3:** GSEA results for each state defined in Fig. 1g.

626 **Table S4:** Differentially expressed genes for RA FLS stimulated with cytokines in vitro.

627 **Table S5:** Genes differentially expressed with the addition of Notch ligand DLL4 to cytokine  
628 stimulation.

629 **Methods**

630

631 **Human synovial tissue:** Synovial tissue was obtained from patients consented into the HSS  
632 FLARE study of RA patients undergoing arthroplasty or synovectomy (IRB no 2014-233). On day  
633 of surgery, samples were cryopreserved in as small fragments in CryoStor CS10 (Stem Cell  
634 Technologies #07959). Synovial tissue quality and grading of synovitis<sup>32</sup> were evaluated by  
635 histologic analysis (H&E).

636

637 **Sample preparation for single cell sequencing:** Synovial tissue samples were disaggregated  
638 into a single-cell suspension as described previously<sup>2</sup>. Briefly, fragments were minced and  
639 enzymatically digested (Liberase TL (Sigma-Aldrich) 100 µg/mL and DNaseI (New England  
640 Biolabs) 100 µg/mL in RPMI) for 30 min at 37°C. Disaggregated cells were assessed for quality  
641 and viability (Nexcelom Cellometer Auto 2000) and then stained with antibodies to CD45 (2D1),  
642 CD31 (WM59), PDPN (NZ-1.3) and Ghost Dye Violet 510 (Tonbo) for fluorescence activated cell  
643 sorting (BD FACSAria III Cell Sorter). Synovial fibroblasts (CD45<sup>-</sup>, CD31<sup>-</sup>, PDPN<sup>+</sup> were collected  
644 directly into FACS buffer. Individual nuclei were prepared using the 10x Genomics protocol  
645 CG000365- Rev A. Nuclei were submitted for sequencing via Chromium Single Cell Multiome  
646 ATAC + Gene Expression (10x Genomics) by the Integrated Genomics Operation core facility at  
647 the Sloan Kettering Institute.

648 For cultured cytokine stimulated FLS, synovial tissues were dissociated into single cells as above,  
649 cultured in MEM alpha (ThermoFisher Scientific Gibco 12561056) with 10% Fetal bovine serum  
650 (R&D systems S11550) as well as 1% penicillin/streptomycin (ThermoFisher Scientific 15070063)  
651 and 1% L-glutamine (ThermoFisher Scientific 25030081). Cells were passaged using TrypLE  
652 Express Enzyme (ThermoFisher Scientific Gibco 12605010) until a FLS monoculture was present  
653 (>3 passages). At passage 4 with TNFα (20 ng/mL) + IFNγ (5 ng/mL) or TNFα (20 ng/mL) + IFNγ  
654 (5 ng/mL) + IL-1β (1 ng/mL) for 24 hours prior to harvesting and isolating nuclei as above.

655 Cytokine sources: recombinant human TNFα from PeproTech (#300-01A), recombinant human  
656 IFNγ from Roche (#11040596001), recombinant human IL-1β from PeproTech (#200-01B).

657

658 **Quantification and Statistical Analysis**

659

660 **Pre-processing of single cell multiome ATAC + gene expression data:** RNA and ATAC  
661 libraries for each patient were aligned using cellranger-arc software (v1.0.0, 10x Genomics)  
662 against 10x genomics reference refdata-cellranger-arc-GRCh38-2020-A using default



663 parameters. The output files `fragments.tsv.gz` and `filtered_feature_matrix.h5` were utilized for  
664 downstream processing and quality control analysis. We then perform the following additional cell  
665 filtering steps: 1) cells with a high fraction of mitochondrial molecules were filtered ( $> 20\%$ ); 2)  
666 clusters resembling contaminating immune cell populations were removed and 3) clusters with  
667 low library complexity were filtered (cells that express very few unique genes). Putative doublets  
668 were removed using the `DoubletDetection` package (<https://doi.org/10.5281/zenodo.2658729>).  
669 Cells or nuclei that passed these QC cutoffs were used to generate sparse count matrices and  
670 filtered `fragments.tsv.gz` files for downstream analysis.

671

## 672 **Single-cell RNA-seq data analysis**

673

674 *Preprocessing, dimensionality reduction, clustering:* Combining the two patient samples yielded  
675 a filtered count matrix of 15736 cells by 36391 genes, with a median of 4156 molecules per cell.  
676 The count matrix was then normalized by library size and scaled to 100,000 per cell for analysis  
677 of the combined dataset. Highly-variable genes were identified using the `Scanpy`  
678 `highly_variable_genes` function with `batch_key='sample'`. Principal component analysis (PCA)  
679 was performed on the normalized expression of highly-variable genes with the top 30 principal  
680 components (PCs) retained. We first performed clustering on the combined dataset using  
681 `Phenograph` with  $k = 30$  to identify 15 clusters. To aid subtype annotation, we merged these  
682 clusters into meta-clusters based on the correlation in cluster mean expression of highly-variable  
683 genes. We then annotated these meta-clusters based on enriched gene pathways identified by  
684 GSEA and previously-published datasets (Alivernini et al<sup>4</sup> and Zhang et al<sup>2</sup>). To evaluate the  
685 amount of batch effect between the two patients, we performed mutual nearest neighbor  
686 correction using `Scanpy`'s `mnn_correct` function. Specifically, we limited the analysis to only the  
687 highly-variable genes and used `svd_dim = 50`.

688

689 *Visualization of single-cell RNA-seq:* To visualize single cells of the two patients, we used UMAP  
690 projections (McInnes et al., 2018) to generate lower dimensional representations using `knn = 30`  
691 and `min_dist = 0.2`.

692

693 *Differential expression in scRNA-seq:* We performed differential expression for the following  
694 comparisons: 1) samples from each cytokine-stimulation conditions vs samples from non-  
695 stimulated, cultured samples (Tables S4), 2) each fibroblast state vs rest (Table S2 tab 2), and 3)  
696 each unsupervised cluster vs rest (Table S2 tab 1). All differential expression was performed

697 using MAST (version 1.8.2)<sup>33</sup>, which provides a flexible framework for fitting a hierarchical  
698 generalized linear model to the expression data. We used a regression model that adjusts for  
699 cellular detection rate (cngeneson, or number of genes detected per sample):

$$700 \quad Y_{i,j} \sim \text{condition} + \text{cngeneson}$$

701 where condition represents the condition of interest and  $Y_{i,j}$  is the expression level of gene  $i$  in  
702 cells in cluster  $j$ , transformed by natural logarithm with a pseudocount of 1.

703 To homogenize cell sampling per condition, we downsampled such that the cell complexity (i.e.  
704 the number of genes per cell) was evenly matched across groups. We partitioned cells from each  
705 group into 10 equally sized bins based on cell complexity and subsampled from each bin to match  
706 cell complexity distribution across samples. We downsampled to at most  $m$  cells per group, where  
707  $m$  is the median number of cells per group. We considered genes to be significantly differentially  
708 expressed for Bonferroni-adjusted  $p$ -value  $< 0.05$ .

709

710 *Identifying enriched gene pathways in single-cell RNA-seq data:* Enriched gene pathways were  
711 identified using pre-ranked GSEA, as implemented by the R package fGSEA<sup>34</sup> using 10,000  
712 permutations. Gene ranks were calculated using  $-\log(p\text{-value}) \times \log \text{fold change}$  based on MAST<sup>33</sup>  
713 differential expression. To assess enriched pathways in clusters, we used HALLMARK and KEGG  
714 subset of Canonical Pathways in MSigDB v 7.1<sup>35</sup>. We considered pathways with Benjamini-  
715 Hochberg adjusted  $p$ -values  $< 0.1$  to be significant.

716

717 *Scoring Gene Signature Expressions:* To score the single-cell expression of gene signatures, we  
718 first transformed the library size-normalized, log-transformed data by z-score and calculated the  
719 average expression of each curated gene set per cell type subtracted from the average  
720 expression of a reference set of genes using the score\_genes function in scanpy. The subsequent  
721 cell type scores were transformed again by z-score. For comparisons to published datasets, we  
722 used the top 30 genes after sorting by adjusted  $p$  value (padj) for top differentially expressed  
723 genes for each unsupervised cluster/cell type.

724

725 *Correlating Spatial Gene Signature Expression:* To correlate the spatial localization of gene  
726 signatures of interest, we computed the pearson correlation coefficient of their expressions across  
727 individual spots for all samples combined. The signatures are generated as described above.

728

## 729 **Single-cell ATAC-seq data analysis**

730

731 *Preprocessing, dimensionality reduction, clustering:* We preprocessed the filtered fragments.tsv  
732 file using the ArchR package<sup>36</sup> v1.0.1. Specifically, we binarized sparse accessibility matrices  
733 binned at 500bp tiles across the genome. We then perform iterative latent semantic indexing (LSI)  
734 on the tile matrix to generate 30 components. For downstream analysis, we filter 3 components  
735 strongly correlated ( $\text{cor} > 0.5$ ) with the number of fragments detected per cell, as well as one  
736 component that is strongly correlated with batch. For visualization, we used the addUMAP  
737 function in ArchR with the following parameters: nNeighbors = 150, minDist = 0.05, metric =  
738 cosine. Clustering was done using the addClusters function in ArchR with the following  
739 parameters: method = "Seurat", knnAssign = 50.

740

741 *Peak-calling and TF motif accessibility scoring:* Filtered fragments for cells in each sample were  
742 aggregated and used as input to the MACS2 peak caller<sup>37</sup>; parameters -f BED, -g 2.7e9, --no-  
743 model, --shift -75, --extsize 150, -q 0.05). Peaks are filtered using an IDR cutoff of 0.05. We  
744 subsequently added motif annotations using "addMotifAnnotations" with the CisBP motif database  
745 and computed chromVAR deviations for each single cell with "addDeviationsMatrix".

746

747 *Identifying enriched motifs per cluster:* To identify differentially accessible motifs for each group  
748 of interest, we used the rank\_genes\_groups function in scanpy with method='wilcoxon' and  
749 corr\_method = 'benjamini-hochberg' on the chromVAR zscore matrix. Motifs were filtered to  
750 include only those for which the corresponding transcription factor was expressed by >20% of  
751 cells in the corresponding FLS state. The top 10 motifs after ranking by 'score' were then selected  
752 for plotting in the heatmap in Fig. 3d.

753

754 **In vitro FLS culture and stimulation for bulk RNA sequencing:** Synovial tissues from 4 donors  
755 (RF<sup>+</sup> and/or CCP<sup>+</sup>) were disaggregated and cultured as above. At passage 4 or 5, cells from the  
756 4 donors were pooled and were plated into 12 well plates at 70,000 cells/well. Cells were allowed  
757 to adhere and were then stimulated with TNF $\alpha$  (0.1 ng/mL), IFN $\gamma$  (0.05 ng/mL), or IL-1 $\beta$  (0.01  
758 ng/mL) alone or in combination for 24 hours in triplicate. For DLL4 treatment, cell culture plates  
759 were coated with recombinant DLL4-FC (R&D systems) overnight at 4°C at 0.5  $\mu\text{g/mL}$  prior to the  
760 addition of FLS and cytokines. Concentrations for all stimuli were determined based on an initial  
761 titration experiment with 4 concentrations per stimulus (10x dilutions starting with 100 ng/mL  
762 TNF $\alpha$ , 50 ng/mL IFN $\gamma$ , 10 ng/mL IL-1 $\beta$  and 5  $\mu\text{g/mL}$  DLL4) and bulk 3' RNA sequencing to  
763 determine the number of differentially expressed genes relative to untreated cells. After  
764 stimulation, we lysed cells, isolated RNA (Zymo Research R1052), prepared libraries (Lexogen

765 QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) for Illumina 015.96) and the Integrated Genomics  
766 Operation at the Sloan Kettering Institute sequenced samples (bulk RNA sequencing).

767

768 **Stimulated FLS bulk RNA sequencing data analysis:** Reads from 3' RNA sequencing of  
769 fibroblasts treated with cytokines were processed using version 2.5.3 of the snakePipes mRNA-  
770 seq pipeline<sup>38</sup> using the flags "--reads '\_R1\_001' '\_R2\_001' --mode 'alignment' --trim --  
771 trimmerOptions '-a A{10}N{90}'". In brief, this pipeline trims reads using Cutadapt, aligns them  
772 using STAR to the genome (release 34 of GRCh38 with Gencode annotations), and then  
773 aggregates gene-level counts using featureCounts. Differentially expressed genes for each  
774 condition were then defined relative to control cells using DESeq2. Genes that were up- or  
775 downregulated at  $p < 0.05$  following correction for multiple hypothesis testing for each single  
776 cytokine treatment were used to define expression signatures for each cytokine. The distributions  
777 shown in Fig. 4b are of the (shrunken)  $\log_2$  fold change estimates of these genes relative to control  
778 cells estimated by DESeq2 in cells treated with the indicated cytokines or combinations of  
779 cytokines.

780

781 **Multicolor immunofluorescence:** Synovial tissue was fixed in 1:4 dilution  
782 Fixation/Permeabilization solution (BD Biosciences Cytofix/Cytoperm Cat No. 554714) in PBS pH  
783 7.4 for 16-20 hours at 4°C. Tissue was washed 3x with PBS then placed in 30% sucrose in 0.1M  
784 sodium phosphate buffer pH 7.4 until the tissue fell to the bottom of the tube (~6 hrs) at which  
785 point tissue was embedded in optimal cutting temperature compound (OCT), frozen on dry ice  
786 and stored at -80°C until sectioning (10  $\mu$ m thick). For staining, tissues were rehydrated on slides,  
787 permeabilized with 0.1% triton in PBS for 10 min and blocked with 5% normal goat serum  
788 (ThermoFisher Scientific 31873) in PBS for 45 min prior to staining with primary antibodies (5 hrs  
789 RT or 21 hrs at 4°C) followed by secondary antibodies (2 hours RT). Appropriate isotype controls  
790 were used on a separate section. After antibody stains, slides were washed, stained for nuclei  
791 (DAPI – ThermoFisher Scientific 62248 – 1:2000 for 5 min RT) and mounted with Fluoromount G  
792 (ThermoFisher 00-4958-02). Images were acquired with a Leica SP8 confocal microscope (40x  
793 oil immersion). Image analysis (merging of channels) was performed with Imaris cell imaging  
794 software.

795

796 **Spatial Transcriptomics:** Fresh synovium was immediately embedded in OCT and frozen using  
797 isopentane cooled by liquid nitrogen. We used Visium Spatial Gene Expression platform (10x  
798 Genomics) in conjunction with the Integrated Genomics Operation and Molecular Cytology core

799 facilities at the Sloan Kettering Institute. For this, tissue was sectioned (10  $\mu$ m sections, 2 tissue  
800 sections in 2 replicates each per slide, capture area 6.5 x 6.5 mm), stained with H&E, and  
801 permeabilized. This was followed by cDNA library construction with spatial barcoding and  
802 sequencing.

803

#### 804 **Spatial transcriptomics data analysis**

805

806 *Preprocessing, dimensionality reduction:* Spatial sequencing data from 2 patients (2 samples  
807 each) were aligned using the Space Ranger (v1.2.2, 10x genomics) pipeline to the 10x genomics  
808 reference genome refdata-gex-GRCh38-2020-A using default parameters to derive a feature  
809 spot-barcode gene expression matrix. Combining the 4 samples yielded a filtered count matrix of  
810 12257 spots by 19809 genes, with a median of 1754 molecules per spot. The count matrix was  
811 then normalized by library size and scaled to the median of total counts of all cells before  
812 normalization for analysis of the combined dataset. We then natural-log transformed the reads  
813 with a pseudocount of 1. Seurat-v3.2 package was then used to select top variable genes for  
814 spatial RNA-seq clustering. Highly-variable genes were identified using the Scanpy  
815 `highly_variable_genes` function with `batch_key='sample'` and `n_top_genes = 2000`. PCA was  
816 performed on the normalized expression of highly-variable genes with the top 50 principal  
817 components (PCs) retained.

818

819 *Scoring Gene Signature Expressions:* To score the single-cell expression of gene signatures, we  
820 further transformed the data by z-score and calculated the average expression of each curated  
821 gene set per cell type subtracted from the average expression of a reference set of genes using  
822 the `score_genes` function in scanpy. The subsequent cell type scores were transformed again by  
823 z-score. Gene signature expressions were visualized using the `scanpy.pl.spatial` function.

824

#### 825 **Antibodies used:**

826 Antibody (vendor; catalog number; clone; lot; dilution – final concentration)

827

#### 828 For sorting FLS:

829 Anti-CD45-FITC (eBiosciences; 11-9459-42, 2D1; lot 4271593; 1:100)

830 Anti-PDPN-APC (Invitrogen; 17-9381-42; NZ-1.3; lot 1988690; 1:100)

831 Anti-CD31- PE/Cy7 (Biolegend; 303118; WM59; lot B276836; 1:100)

832 Ghost Dye Violet 510 (Tonbo; 13-0870-T100; no clone; lot D0870040521133; 1:1000)

833

834 For immunofluorescence:

835 Primary:

836 Anti-PDPN (Invitrogen; 14-9381-82; NZ-1.3; lot 2400405; 1:100 – final 5 µg/mL)

837 Anti-HLA.DR-AF488 (Biolegend; 307620; L243; lot B271228; 1:100 – 2 µg/mL)

838 Anti-CD3-BV480 (BD biosciences; 566105; UCHT1; lot 0079903; 1:100)

839 Anti-CD8-AF647 (Biolegend; 344725; SK1; lot B270006; 1:50 – final 1 µg/mL)

840 Anti-pSTAT1-PE (Biolegend; 686403; A15158B; lot B327686; 1:50 – final 0.12 µg/mL)

841 Anti-CD68-AF488 (Biolegend; 333812; Y1/82A; lot B278908; 1:10 – final 2.4 µg/mL)

842 Anti-CD19-PE (Biolegend; 302208; HIB19; lot B273506; 1:20 – final 2.5 µg/mL)

843 Anti-CD90-AF700 (R&D systems; FAB2067N; Thy1A1; lot 1569061; 1:50 – final 4 µg/mL)

844 Anti-CD34-AF647 (Biolegend; 343507; 581; lot B312791; 1:100 – final 2 µg/mL)

845

846 Secondary:

847 Anti-rat-AF594 (Biolegend; 405422; polyclonal; lot B302011; 1:1000)